Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib

Journal of Investigative Dermatology

Volumn 134, Issue 4, 2014, Pages 992-1000

  Okiyama, Naoko ^a   Furumoto, Yasuko ^b   Villarroel, Vadim A ^a   Linton, Jay T ^a   Tsai, Wanxia L ^b   Gutermuth, Jan ^a   Ghoreschi, Kamran ^b   Gadina, Massimo ^b   O'Shea, John J ^b   Katz, Stephen I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; TOFACITINIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL DEATH; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN DEFECT; T LYMPHOCYTE ACTIVATION; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; BONE MARROW; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINES; CYTOKINES; DERMATITIS; GENE EXPRESSION REGULATION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-2; KERATINOCYTES; MICE; MICE, INBRED C57BL; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES;

EID: 84897068116     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.476     Document Type: Article

References (39)

1. Blazar BR, Murphy WJ, Abedi M (2012) Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 12:443-58
2. Boy MG, Wang C, Wilkinson BE et al. (2009) Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690, 550 in patients with psoriasis. J Invest Dermatol 129:2299-302
3. Chen X, Vodanovic-Jankovic S, Johnson B et al. (2007) Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 110:3804-13
4. Coghill JM, Sarantopoulos S, Moran TP et al. (2011) Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood 117:3268-76
5. Conklyn M, Andresen C, Changelian P et al. (2004) The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing. J Leukoc Biol 76:1248-55
6. Ferrara JL, Levine JE, Reddy P et al. (2009) Graft-versus-host disease. Lancet 373:1550-61
7. Ghoreschi K, Laurence A, O'Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228:273-87
8. Ikehara S (2010) The future of stem cell transplantation in autoimmune disease. Clin Rev Allergy Immunol 38:292-7
9. Johnston JA, Kawamura M, Kirken RA et al. (1994) Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 370:151-3
10. Karaman MW, Herrgard S, Treiber DK et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-32
11. Khor SS, Miyagawa T, Toyoda H et al. (2013) Genome-wide association study of HLA-DQB1*06:02 negative essential hypersomnia. Peer J 1:e66
12. Konoeda F, Shichita T, Yoshida H et al. (2010) Therapeutic effect of IL-12/23 and their signaling pathway blockade on brain ischemia model. Biochem Biophys Res Commun 402:500-6
13. Kremer JM, Bloom BJ, Breedveld FC et al. (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690, 550 versus placebo. Arthritis Rheum 60:1895-905
14. Kremer JM, Cohen S, Wilkinson BE et al. (2012) A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 64:970-81
15. Kudlacz E, Conklyn M, Andresen C et al. (2008) The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol 582:154-61
16. Kudlacz E, Perry B, Sawyer P et al. (2004) The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 4:51-7
17. Maraninchi D, Mawas C, Guyotat D et al. (1988) Selective depletion of marrow-T cytotoxic lymphocytes (CD8) in the prevention of graft-versus-host disease after allogeneic bone-marrow transplantation. Transplant Int 1:91-4
18. Milici AJ, Kudlacz EM, Audoly L et al. (2008) Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 10:R14
19. Miyagawa F, Gutermuth J, Zhang H et al. (2010) The use of mouse models to better understand mechanisms of autoimmunity and tolerance. J Auto-immun 35:192-8
20. Miyagawa F, Okiyama N, Villarroel V et al. (2013) Identification of CD3CD4CD8T cells as potential regulatory cells in an experimental murine model of graft vs. host skin disease (GvHD). J Invest Dermatol 133:2538-45
21. Miyagawa F, Tagaya Y, Kim BS et al. (2008) IL-15 serves as a costimulator in determining the activity of autoreactive CD8 T cells in an experimental mouse model of graft-versus-host-like disease. J Immunol 181:1109-19
22. Muller M, Briscoe J, Laxton C et al. (1993) The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and-gamma signal trans-duction. Nature 366:129-35
23. O'Shea JJ, Plenge R (2012) JAK and STAT signaling molecules in immunor-egulation and immune-mediated disease. Immunity 36:542-50
24. Okiyama N, Sugihara T, Oida T et al. (2012) T lymphocytes and muscle condition act like seeds and soil in a murine polymyositis model. Arthritis Rheum 64:3741-9
25. Palathumpat V, Dejbakhsh-Jones S, Strober S (1995) The role of purified CD8+ T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation. Transplantation 60:355-61
26. Papp KA, Menter A, Strober B et al. (2012) Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 167:668-77
27. Park HB, Oh K, Garmaa N et al. (2010) CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-gamma pathway. Transplantation 90:825-35
28. Pesu M, Laurence A, Kishore N et al. (2008) Therapeutic targeting of Janus kinases. Immunol Rev 223:132-42
29. Ports WC, Khan S, Lan S et al. (2013) A randomised Phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 169:137-45
30. Ringden O, Le Blanc K (2005) Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives. APMIS 113:813-30
31. Rodig SJ, Meraz MA, White JM et al. (1998) Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93:373-83
32. Roifman CM (2010) Hematopoietic stem cell transplantation for profound T-cell deficiency (combined immunodeficiency). Immunol Allergy Clin North Am 30:209-19
33. Sandborn WJ, Ghosh S, Panes J et al. (2012) Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367:616-24
34. Schroeder MA, DiPersio JF (2011) Mouse models of graft-versus-host disease: advances and limitations. Dis Model Mech 4:318-33
35. Shibaki A, Sato A, Vogel JC et al. (2004) Induction of GVHD-like skin disease by passively transferred CD8(+) T-cell receptor transgenic T cells into keratin 14-ovalbumin transgenic mice. J Invest Dermatol 123:109-15
36. Sontheimer RD (2009) Lichenoid tissue reaction/interface dermatitis: clinical and histological perspectives. J Invest Dermatol 129:1088-99
37. Tanaka Y, Maeshima Y, Yamaoka K (2012) In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Ann Rheum Dis 71 Suppl 2: i70-4
38. Toubai T, Tanaka J, Paczesny S et al. (2012) Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)? Curr Stem Cell Res Ther 7:229-39
39. Yi T, Zhao D, Lin CL et al. (2008) Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood 112:2101-10